Quest Diagnostics Cash Flow from Operating Activities 2010-2023 | DGX

Quest Diagnostics annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2023. Cash flow from operating activities can be defined as a company's cash flows from operations.
  • Quest Diagnostics cash flow from operating activities for the quarter ending December 31, 2023 was $1.272B, a 25.96% decline year-over-year.
  • Quest Diagnostics cash flow from operating activities for the twelve months ending December 31, 2023 was $2.649B, a 40.66% decline year-over-year.
  • Quest Diagnostics annual cash flow from operating activities for 2023 was $1.272B, a 25.96% decline from 2022.
  • Quest Diagnostics annual cash flow from operating activities for 2022 was $1.718B, a 23.06% decline from 2021.
  • Quest Diagnostics annual cash flow from operating activities for 2021 was $2.233B, a 11.37% increase from 2020.
Quest Diagnostics Annual Cash Flow Ops
(Millions of US $)
2023 $1,272
2022 $1,718
2021 $2,233
2020 $2,005
2019 $1,243
2018 $1,200
2017 $1,175
2016 $1,116
2015 $821
2014 $944
2013 $652
2012 $1,187
2011 $895
2010 $1,118
2009 $997
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $15.639B $9.252B
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $17.291B 10.46
DaVita (DVA) United States $11.979B 14.88
Encompass Health (EHC) United States $8.677B 22.21
Chemed (CHE) United States $8.611B 26.69
Elanco Animal Health (ELAN) United States $8.401B 21.80
Option Care Health (OPCH) United States $5.230B 19.80
RadNet (RDNT) United States $4.117B 85.72
Amedisys (AMED) United States $3.117B 22.08
LifeStance Health (LFST) United States $2.741B 0.00
Astrana Health (ASTH) United States $2.193B 29.66
Addus HomeCare (ADUS) United States $1.810B 25.90
U.S Physical Therapy (USPH) United States $1.582B 42.33
Pennant (PNTG) United States $0.703B 37.13
Aveanna Healthcare Holdings (AVAH) United States $0.477B 0.00
Atai Life Sciences (ATAI) Germany $0.325B 0.00
Daxor (DXR) United States $0.045B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.027B 0.00
ATI Physical Therapy (ATIP) United States $0.022B 0.00
Psychemedics (PMD) United States $0.015B 0.00
Ontrak (OTRK) United States $0.013B 0.00
Novo Integrated Sciences (NVOS) United States $0.011B 0.00
IMAC Holdings (BACK) United States $0.004B 0.00